<DOC>
	<DOCNO>NCT00949039</DOCNO>
	<brief_summary>Randomised phase 3 trial compare 2 arm : experimental treatment ( Isolated pelvis perfusion ) standard treatment ( systemic chemotherapy +/- radiotherapy +/- surgery ) . Patients include non resectable , recurrent gynaecologic digestive pelvic cancer . The aim study show 25 % increase 1 year overall survival rate isolate pelvic perfusion .</brief_summary>
	<brief_title>Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg Melphalan 1.5 mg/kg Versus Standard Treatment Patients With Non Resectable , Recurrent Gynaecologic Digestive Pelvic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Histologically prove locally advanced gynaecologic digestive tumour ( epidermoid carcinoma , adenocarcinoma , neuroendocrine tumour , sarcomas melanoma ) , ( cervix , vagina , rectal , anal ) . Locally recurrent tumour surgical treatment mutilate marginal ( R1 R2 ) and/or cervix cancer , primary tumour non accessible standard treatment ( radiotherapy chemotherapy brachytherapy surgery ) . Surgically resectable tumour ( R0 type ) patient agree surgery . Patients age 18 76 an Performance OMS Index ≤ 2 Normal biologic parameter Good general cardiac state ( ASA I II NYHA I II ) Surgically resectable tumour ( RO ) peritoneal tumour extension distant metastasis . Cardiac vascular pathology Pulmonary disease Uncontrolled Sepsis disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>